DRTSHealthcare · BiotechnologyThe 5 Wall Street analysts covering Alpha Tau Medical Ltd. hold a median 12-month price target of $17 — +21.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Alpha Tau Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DRTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Sept 2026 | Barclays | Maintains | Overweight | $17 → $30 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $16 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 4 June 2026 | Barclays | Maintains | Overweight | — |
| 4 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2026 | Piper Sandler | Maintains | Neutral | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Ladenburg Thalmann | Maintains | Buy | — |
| 11 Mar 2026 | Citigroup | Maintains | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2026 | Piper Sandler | Downgrade | Neutral | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Dec 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRTS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Alpha Tau Medical Ltd. returned +235.7% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 3% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alpha Tau Medical Ltd. has a market value of $1.3B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.6M.
Trailing P/E: −26.5×; forward P/E: −26.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alpha Tau Medical Ltd. employs 121 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alpha Tau Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alpha Tau Medical announced that company management will participate in investor conferences in October 2026. The announcement was made on October 5, 2026, from Jerusalem.
Why it matters — DRTS watchers may learn more about the company's progress and outlook through management's presentations at these upcoming investor conferences.
Alpha Tau is approaching a potential year-end inflection point, with glioblastoma (GBM) data expected before year-end and pancreatic data shortly after. Two of the first three GBM patients reportedly achieved a complete response, an outcome described as essentially unheard of in GBM.
Why it matters — A DRTS watcher would care because upcoming GBM and pancreatic data represent potential milestone catalysts for the company, with early GBM responses suggesting a possible breakthrough.
Alpha Tau Medical Ltd. announced that it will participate in investor conferences in September 2026. The announcement was made from the company's Jerusalem headquarters.
Why it matters — A DRTS watcher would care because the company's participation in investor conferences provides opportunities for greater visibility and engagement with the investment community, without indicating any specific financial or operational changes.
Alpha Tau Medical announced it has completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for newly diagnosed unresectable pancreatic cancer. Enrollment was expanded three times from an original 12 patients to 48 treated patients due to strong demand, with data release targeted for early 2027.
Why it matters — Successful completion of enrollment, after multiple expansions driven by clinician and patient demand, advances a key milestone in Alpha Tau's global pancreatic cancer program and informs the design of a planned pivotal study.
The 5 Wall Street analysts covering Alpha Tau Medical Ltd. have a median 12-month price target of $17, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Alpha Tau Medical Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Tau Medical Ltd. 15 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Alpha Tau Medical Ltd. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +21.4% from the last close, and Ticker Nerd's factor model ranks Alpha Tau Medical Ltd. 15 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alpha Tau Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.
Alpha Tau Medical Ltd. returned +235.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing Alpha DaRT, a targeted alpha-radiation platform designed for the treatment of solid tumors.
The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Alpha Tau to Participate in October Investor Conferences". Alpha Tau Medical announced that company management will participate in investor conferences in October 2026. The announcement was made on October 5, 2026, from Jerusalem.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on developing Alpha DaRT, a targeted alpha-radiation platform designed for the treatment of solid tumors. The company’s core work centers on research, clinical development, and commercialization of localized cancer therapies that deliver alpha particles directly inside tumor tissue while limiting exposure to surrounding healthy tissue. Alpha Tau Medical Ltd. is active in a range of oncology indications, including skin, oral, pancreatic, prostate, lung, liver, breast, and brain cancers, reflecting the broad potential use of its technology across difficult-to-treat solid tumors. Headquartered in Jerusalem, Israel, the company operates as a medical technology business serving the oncology sector and is centered on advancing precision radiation approaches for cancer care.
CEO Mr. Uzi Sofer · 121 employees · Israel · https://www.alphatau.com
